As some national guidelines now recommend against routine prostate cancer screening, the overall rate of men receiving treatment for the disease declined 42 percent, a new study finds.
There is perhaps no hotter topic in prostate cancer treatment today than the use of prostate cancer biomarkers. To learn more about them, we posed a few questions to Todd Morgan, M.D., a surgeon in the U-M Multidisciplinary Urologic Oncology Clinic.
Todd Morgan, M.D. of the U-M Multidisciplinary Urologic Oncology Clinic answers questions about prostate cancer biomarkers and explains how they help in prostate cancer treatment.
A new paper looks at how MRI and a clear understanding of the functional anatomy around the prostate can allow radiation oncologists to plan a course of treatment for patients with prostate cancer that spares these critical structures.
University of Michigan researchers have discovered a biomarker that may be a potentially important breakthrough in diagnosing and treating prostate cancer.
Researchers have developed a new drug candidate that shows potential in laboratory studies against a rare type of acute leukemia. And additional studies suggest the same compound could play a role in prostate cancer treatment as well.
MENU
